Prognosis
Fauci Calls Data From Gilead Virus-Drug Trial ‘Good News’
- Remdesivir helped patients recover more quickly, company says
- Markets rally on hope treatment could help ease economic pain
This article is for subscribers only.
Sign up here for our daily coronavirus newsletter on what you need to know, and subscribe to our Covid-19 podcast for the latest news and analysis.
The U.S. government’s top infectious-disease expert said that early results of a closely watched clinical trial offered “quite good news” regarding a potential Covid-19 therapy made by the biotechnology company Gilead Sciences Inc.